Description: Everest Medicines Limited, a biopharmaceutical company, engages in discovery, licensing, clinical development, and commercialization of therapies to address critical unmet medical needs in Greater China and other Asia Pacific markets. Its pipeline products include eleven clinical-stage drug candidates for the treatment of oncology, immunology, cardio-renal, and infectious diseases. Everest Medicines Limited was incorporated in 2017 and is headquartered in Shanghai, China.
Home Page: www.everestmedicines.com
Plaza 66
Shanghai,
200040
China
Phone:
Officers
| Name | Title |
|---|---|
| Mr. Wei Fu | Exec. Chairman |
| Mr. Yongqing Luo | CEO & Exec. Director |
| Mr. Ian Ying Woo | CFO, Pres & Exec. Director |
| Mr. Neo Xiaofan Zhang | COO & Exec. Director |
| Dr. Wei Yang Ph.D. | Chief Scientific Officer |
| Dr. Kerry Levan Blanchard M.D., Ph.D. | Advisor |
| Ms. Yang Shi | Chief Medical Officer - Oncology/Immunology |
| Dr. Zhengying Zhu M.D., Ph.D. | Chief Medical Officer - Internal Medicine |
| Ms. Xu Zhu | Chief Medical Officer - Infectious Disease |
| Dr. Jason M. Brown Ph.D. | Chief Bus. Officer |
Exchange: HK
Country: HK
Currency: Hong Kong Dollar (HK$)
| Forward PE: | 4.4743 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.7485 |
| Price-to-Sales TTM: | 3735.6294 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 476 |